What is the SYNAPSE-CMT Clinical Trial?

CMTA-STAR Alliance Partner NMD Pharma has recently started screening and enrolling patients in the SYNAPSE-CMT Phase II trial. This trial aims to evaluate the safety, tolerability, and potential effectiveness of an investigational medication, NMD670.

NMD670 is a novel medication that works by enhancing communication between nerves and muscles, a common issue for people living with CMT. The hope is that this treatment will improve your strength, endurance, and overall daily functioning. By joining the study, you’ll play a critical role in determining whether this therapy could help others with CMT in the future.

Why Participate in the SYNAPSE-CMT Clinical Trial?

By participating, you contribute to critical research that could pave the way for new therapies for CMT. Participants will receive all study-related evaluations, medications, and supplies at no cost. Reasonable travel expenses will be reimbursed, and you will play a direct role in advancing potential treatments for the CMT community.

Who Can Participate?

If you are between the ages of 18-70 and have been diagnosed with CMT1 or CMT2, you are able to complete basic walking tests without the assistance of ankle-foot orthoses (AFOs), you may qualify. During the study, you’ll either receive NMD670 or a placebo over a 21-day period, with regular assessments to monitor your progress.

Where is the Trial Taking Place?

The SYNAPSE-CMT study is being conducted across multiple sites in the United States and Europe. Currently enrolling US sites include locations in New York, Boston, Kansas, Ohio, and Washington, with others opening soon. Most sites are offering to share their contact information with interested patients/families, but some may not be willing to share that publicly.  If the contact information is available on Clinicaltrials.gov, that means they have agreed to share publicly.  If a site has not offered to share publicly, interested parties can contact us at NMD Pharma with questions, and we can help facilitate answers to questions and connection to sites.  Email at contact@nmdpharma.com

CMTA-STAR’s Role in Advancing Research

As the global leader in driving progress for all types of CMT, CMTA is proud to support CMTA-STAR Alliance Partner NMD Pharma. Together, we are committed to patient-centered research prioritizing real-world impacts for those living with CMT. Your participation in the SYNAPSE-CMT trial exemplifies the power of collaboration between researchers, clinicians, and the patient community.

How to Participate

If you meet the eligibility criteria and wish to take part in the SYNAPSE-CMT Phase II clinical trial:

• Contact NMD Pharma at contact@nmdpharma.com.
• Visit SYNAPSE-CMT trial for official study information.

Register with Patients as Partners in Research Today

Not yet registered with Patients as Partners in Research but wish to be informed about more opportunities like the SYNAPSE-CMT trial? Click the button below to register today! Registering today ensures you will be the first to hear when NMD Pharma announces new trial locations. Registering also ensures you are updated on all the latest news and developments in CMT research. Registration is free and secure, and all who have CMT are invited to register.